Ephedrine Sulfate Injection Receives FDA Nod

Article

The FDA recently approved Endo International and Par Pharmaceutical’s new drug application for its 50 mg/ml ephedrine sulfate injection.

The FDA recently approved Endo International and Par Pharmaceutical’s new drug application for its 50 mg/ml ephedrine sulfate injection.

The drug, a parenterally administered pressor agent, is indicated for the treatment of clinically important hypotension in surgery.

Adverse events associated with the use of ephedrine sulfate include nausea, vomiting, and tachycardia. The FDA also warned that the concomitant use of the medication with oxytocic drugs could result in pressor effects, and that repeated administration could lead to tachyphylaxis.

Par Pharmaceuticals plans to launch its 50 mg/ml ephedrine sulfate injection as packaged cartons of 25 single-use vials in February 2017.

Related Videos
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT | stock.adobe.com
Pharmacist helping patient use glucose monitor -- Image credit: Kalyakan | stock.adobe.com
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.